Clinical Trial Update: Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy

View source ↗

Summary

A Massachusetts General Hospital clinical trial is investigating cerebrospinal fluid biomarkers in myotonic dystrophy type 1. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myotonic Dystrophy Type

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Myotonic Dystrophy Type 1 | Status: RECRUITING